Perceptive Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

Perceptive Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-400,000	Closed	-$2.16M	–	141
2020 Q4	$2.16M	Hold	400,000	–	–	0.02%	130
2020 Q3	$3.19M	Hold	400,000	–	–	0.05%	109
2020 Q2	$4M	Buy	+400,000	New	+$2.51M	0.06%	99
2018 Q3	–	Sell	-49,302	Closed	-$585K	–	118
2018 Q2	$585K	Buy	+49,302	New	+$615K	0.02%	106

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Perceptive Advisors's ADAP Position: Q1 2021 in Review

Perceptive Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q1 2021, closing a stake of 400,000 shares — an estimated $2.16M sold.

Perceptive Advisors first reported a position in ADAP in Q2 2018 and held it in 4 quarters. The position peaked at $4M in Q2 2020. 84 funds tracked by Wall St. Rank hold ADAP as of Q1 2021.

Perceptive Advisors reported no remaining Adaptimmune Therapeutics position as of Q1 2021 after selling out during the quarter.
Perceptive Advisors sold 400,000 Adaptimmune Therapeutics shares in Q1 2021, an estimated $2.16M.
Perceptive Advisors first reported a position in Adaptimmune Therapeutics in Q2 2018 and held it in 4 quarters.
Perceptive Advisors's Adaptimmune Therapeutics position peaked at $4M in Q2 2020.
84 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2021.

Based on Perceptive Advisors's 13F filing for Q1 2021, filed 17 May 2021.